Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics

NEW YORK, July 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.

--
Synageva BioPharma Corp. Analyst Notes
On June 30, 2014, Synageva BioPharma Corp. (Synageva) reported that its global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial for sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency (LAL Deficiency) earned positive top-line results by reaching primary endpoint of normalization of alanine aminotransferase (ALT), a marker of liver injury. According to the Company, when measured by various secondary endpoints, sebelipase alfa showed that it also improved other disease-related abnormalities. Sanj K. Patel, President and CEO, Synageva said, "The positive Phase 3 results with sebelipase alfa are an important step forward for patients and families affected by LAL Deficiency. We will continue to build towards a sustainable and generational company that is committed to helping patients with rare and devastating diseases." The full analyst notes on Synageva are available to download free of charge at:

http://www.analystsreview.com/Jul-03-2014/GEVA/report.pdf

--
Opko Health Inc. Analyst Notes
On June 27, 2014, Opko Health Inc. (OPKO) announced that it received a patent grant that covers the Company's long-acting CTP-enhanced human growth hormone product (Lagova), including composition of matter and associated methods from the European Patent Office. According to the Company, the new patent will provide OPKO with additional intellectual property protection that will cover Lagova in Europe, on top of other previously granted patents in the U.S. by the U.S. Patent and Trademark Office. OPKO added that it recently announced strong positive results from a Phase 2 study of Lagova in children with growth hormone deficiency, while Lagova's Phase 3 study in adults with growth hormone deficiency is currently ongoing. The full analyst notes on OPKO are available to download free of charge at:

http://www.analystsreview.com/Jul-03-2014/OPK/report.pdf

--
bluebird bio Inc. Analyst Notes
On June 30, 2014, bluebird bio Inc. (bluebird bio) announced that it has acquired Precision Genome Engineering, Inc., (Pregenen), a biotechnology company which develops gene editing and cell signaling technologies with a broad range of potential therapeutic applications. Nick Leschly, Chief bluebird said, "We are excited to add Pregenen's team and their unique gene editing platform to bluebird as it will further expand and lever our gene therapy product platform. While we remain focused on driving our core programs forward, this acquisition represents a significant investment in our stated strategy to integrate emerging technologies that can enhance our ability to develop innovative and potentially transformative gene therapy and cancer immunotherapy products for patients." The full analyst notes on bluebird bio are available to download free of charge at:

http://www.analystsreview.com/Jul-03-2014/BLUE/report.pdf

--
BioDelivery Sciences International, Inc. Analyst Notes
On June 26, 2014, BioDelivery Sciences International, Inc. (BioDelivery Sciences) announced the completion of enrollment of all patients required for the Company's initial Phase 3 RHAPSODY Study, a multicenter, randomized, double-blind, placebo-controlled study organized to determine the efficacy and safety of Clonidine Topical Gel in the treatment of the pain associated with painful diabetic neuropathy (PDN). According to the Company, in the study, 140 adult patients have been randomized into the 12-week double-blind treatment phase, who received either Clonidine Topical Gel or a placebo gel. These are the first two pivotal trials required while filing a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). BioDelivery Sciences stated that the FDA has granted the program with Fast Track designation, recognizing the need to develop new therapies for this serious condition. Dr. Andrew Finn, Executive Vice President of Product Development, BioDelivery Sciences said, "We are very pleased with the rapid progression of this study, which we expect will allow for an independent interim analysis based on 50% of the patients completed during the third quarter of this year - one quarter ahead of schedule." The full analyst notes on BioDelivery Sciences are available to download free of charge at:

http://www.analystsreview.com/Jul-03-2014/BDSI/report.pdf

--
Haemonetics Corporation Analyst Notes
On June 30, 2014, Haemonetics Corporation (Haemonetics) announced that it will issue a press release discussing its earnings for Q1 FY 2015 on Wednesday, July 30, 2014, before the market opens, followed by a conference call at 8:00 a.m. ET to discuss and answer questions regarding the results. The Company announced that the webcast will be available at its website, where a replay can also be accessed after 11:00 a.m. ET. The replay of the webcast will remain at the Company's website until August 6, 2014. The full analyst notes on Haemonetics are available to download free of charge at:

http://www.analystsreview.com/Jul-03-2014/HAE/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review